Home > Publications database > A costimulatory chimeric antigen receptor targeting TROP2 enhances the cytotoxicity of NK cells expressing a T cell receptor reactive to human papillomavirus type 16 E7. > print

001     276212
005     20240229154958.0
024 7 _ |a 10.1016/j.canlet.2023.216242
|2 doi
024 7 _ |a pmid:37217069
|2 pmid
024 7 _ |a 0304-3835
|2 ISSN
024 7 _ |a 1872-7980
|2 ISSN
024 7 _ |a altmetric:148839521
|2 altmetric
037 _ _ |a DKFZ-2023-01024
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Quiros-Fernandez, Isaac
|0 P:(DE-HGF)0
|b 0
|e First author
245 _ _ |a A costimulatory chimeric antigen receptor targeting TROP2 enhances the cytotoxicity of NK cells expressing a T cell receptor reactive to human papillomavirus type 16 E7.
260 _ _ |a Amsterdam [u.a.]
|c 2023
|b Elsevier Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1687349241_6283
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:D122#LA:D122# / 2023 Jul 10;566:216242
520 _ _ |a Immune cells modified to express a tumor-reactive T cell receptor (TCR) have shown limited efficacy as stand-alone therapy against solid tumors. Genital and oropharyngeal carcinomas induced by human papillomavirus (HPV) type 16 express constitutively its E6 and E7 oncoproteins, which makes them convenient targets for adoptive cell immunotherapy. However, viral antigen presentation by tumor cells is low and limits the anti-tumor efficacy of CD8+ T cells. To enhance the functionality of immune effector cells, we have devised a strategy combining a costimulatory chimeric antigen receptor (CAR) with a TCR. We used a clinically tested TCR specific to E7 (E7-TCR) of HPV16 and a newly constructed CAR targeting the trophoblast cell surface antigen 2 (TROP2), which carried the intracellular costimulatory domains CD28 and 4-1BB, but was devoid of the CD3ζ domain. Flow cytometry analyses showed a notable upregulation of activation markers and of cytolytic molecule release by NK-92 cells genetically engineered to express CD3, CD8 and both E7-TCR and TROP2-CAR, after co-incubation with HPV16+ cervical cancer cells. Furthermore, the E7-TCR/TROP2-CAR NK-92 cells demonstrated enhanced antigen-specific activation and augmented cytotoxicity against tumor cells compared with NK-92 cells expressing the E7-TCR alone. A costimulatory TROP2-CAR can synergistically cooperate with the E7-TCR in NK cells thereby enhancing their signaling strength and antigen-specific cytotoxicity. This approach might improve the outcome of adoptive cell immunotherapies for HPV16+ cancer patients currently under investigation.
536 _ _ |a 314 - Immunologie und Krebs (POF4-314)
|0 G:(DE-HGF)POF4-314
|c POF4-314
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Cervical cancer
|2 Other
650 _ 7 |a Chimeric antigen receptor CAR
|2 Other
650 _ 7 |a Head and neck squamous cell carcinoma
|2 Other
650 _ 7 |a Human papillomavirus HPV
|2 Other
650 _ 7 |a Natural killer cell NK
|2 Other
650 _ 7 |a T cell receptor TCR
|2 Other
650 _ 7 |a TROP2
|2 Other
700 1 _ |a Poorebrahim, Mansour
|0 P:(DE-He78)081f0df0551762b7dbb2faabe23023b5
|b 1
|e First author
|u dkfz
700 1 _ |a Marmé, Frederik
|b 2
700 1 _ |a Burdach, Stefan Eg
|b 3
700 1 _ |a Cid-Arregui, Angel
|0 P:(DE-He78)a30064f6b2d9ab959d35315d7668c091
|b 4
|e Last author
|u dkfz
773 _ _ |a 10.1016/j.canlet.2023.216242
|g p. 216242 -
|0 PERI:(DE-600)2004212-7
|p 216242
|t Cancer letters
|v 566
|y 2023
|x 0304-3835
909 C O |p VDB
|o oai:inrepo02.dkfz.de:276212
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)081f0df0551762b7dbb2faabe23023b5
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)a30064f6b2d9ab959d35315d7668c091
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-314
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Immunologie und Krebs
|x 0
914 1 _ |y 2023
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-03-30
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-03-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-03-30
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-08-24
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-08-24
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCER LETT : 2022
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-24
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-24
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CANCER LETT : 2022
|d 2023-08-24
920 2 _ |0 I:(DE-He78)D122-20160331
|k D122
|l D122 AG Gezielte Tumorvakzine
|x 0
920 1 _ |0 I:(DE-He78)D122-20160331
|k D122
|l D122 AG Gezielte Tumorvakzine
|x 0
920 0 _ |0 I:(DE-He78)D122-20160331
|k D122
|l D122 AG Gezielte Tumorvakzine
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)D122-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21